Prediction of Staphylococcus aureus Antimicrobial Resistance by Whole-Genome Sequencing

ABSTRACT Whole-genome sequencing (WGS) could potentially provide a single platform for extracting all the information required to predict an organism's phenotype. However, its ability to provide accurate predictions has not yet been demonstrated in large independent studies of specific organisms. In this study, we aimed to develop a genotypic prediction method for antimicrobial susceptibilities. The whole genomes of 501 unrelated Staphylococcus aureus isolates were sequenced, and the assembled genomes were interrogated using BLASTn for a panel of known resistance determinants (chromosomal mutations and genes carried on plasmids). Results were compared with phenotypic susceptibility testing for 12 commonly used antimicrobial agents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) performed by the routine clinical laboratory. We investigated discrepancies by repeat susceptibility testing and manual inspection of the sequences and used this information to optimize the resistance determinant panel and BLASTn algorithm. We then tested performance of the optimized tool in an independent validation set of 491 unrelated isolates, with phenotypic results obtained in duplicate by automated broth dilution (BD Phoenix) and disc diffusion. In the validation set, the overall sensitivity and specificity of the genomic prediction method were 0.97 (95% confidence interval [95% CI], 0.95 to 0.98) and 0.99 (95% CI, 0.99 to 1), respectively, compared to standard susceptibility testing methods. The very major error rate was 0.5%, and the major error rate was 0.7%. WGS was as sensitive and specific as routine antimicrobial susceptibility testing methods. WGS is a promising alternative to culture methods for resistance prediction in S. aureus and ultimately other major bacterial pathogens.

[1]  A. Whitelaw,et al.  Genetic basis of rifampicin resistance in methicillin-resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa , 2012, BMC Microbiology.

[2]  S. Rasmussen,et al.  Identification of acquired antimicrobial resistance genes , 2012, The Journal of antimicrobial chemotherapy.

[3]  A. Kwon,et al.  Extended Spectrum of Quinolone Resistance, Even to a Potential Latter Third-Generation Agent, as a Result of a Minimum of Two GrlA and Two GyrA Alterations in Quinolone-Resistant Staphylococcus aureus , 2010, Chemotherapy.

[4]  E. Birney,et al.  Velvet: algorithms for de novo short read assembly using de Bruijn graphs. , 2008, Genome research.

[5]  F. Tubau,et al.  Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain , 2010, BMC Microbiology.

[6]  K. Bowker,et al.  Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. , 1998, The Journal of antimicrobial chemotherapy.

[7]  D. Hughes,et al.  Genetic and Phenotypic Identification of Fusidic Acid-Resistant Mutants with the Small-Colony-Variant Phenotype in Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.

[8]  I. Chopra,et al.  Distribution of Fusidic Acid Resistance Determinants in Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[9]  T. Morris,et al.  Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin , 2011, Chemotherapy.

[10]  P. Hsueh,et al.  Fusidic Acid Resistance Determinants in Staphylococcus aureus Clinical Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[11]  K. Walker-Bone,et al.  Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia , 2010, International journal of microbiology.

[12]  M. Tanaka,et al.  Mechanism of quinolone resistance in Staphylococcus aureus , 2000, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[13]  A. Myllyniemi,et al.  Comparison of Tests for Detection of β-Lactamase-Producing Staphylococci , 2007, Journal of Clinical Microbiology.

[14]  D. Hughes,et al.  Genetic Determinants of Resistance to Fusidic Acid among Clinical Bacteremia Isolates of Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[15]  Ning Ma,et al.  BLAST+: architecture and applications , 2009, BMC Bioinformatics.

[16]  P. Francioli,et al.  Unusual spread of a penicillin-susceptible methicillin-resistant Staphylococcus aureus clone in a geographic area of low incidence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Fishwick,et al.  Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. , 2009, The Journal of antimicrobial chemotherapy.

[18]  M. Struelens,et al.  Evaluation of the Vitek 2 system for identification and antimicrobial susceptibility testing of Staphylococcus spp. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  Julian Parkhill,et al.  Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study , 2011, The Lancet. Infectious diseases.

[20]  D. Ince,et al.  Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions , 2000, Antimicrobial Agents and Chemotherapy.

[21]  Ronald N. Jones,et al.  Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008 , 2010, Antimicrobial Agents and Chemotherapy.

[22]  T. Wichelhaus,et al.  Molecular analysis of fusidic acid resistance in Staphylococcus aureus , 2003, Molecular microbiology.

[23]  Daniel J. Wilson,et al.  Whole-Genome Sequencing Shows That Patient-to-Patient Transmission Rarely Accounts for Acquisition of Staphylococcus aureus in an Intensive Care Unit , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Dougan,et al.  Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology , 2012, PLoS pathogens.

[25]  B. Barrell,et al.  Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Kaatz,et al.  Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[27]  Peter Donnelly,et al.  Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease , 2012, Proceedings of the National Academy of Sciences.

[28]  Yasuhiro Suzuki,et al.  Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. , 2003, Diagnostic microbiology and infectious disease.

[29]  L. Peterson,et al.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli , 1990, Journal of bacteriology.

[30]  J. Andrews BSAC standardized disc susceptibility testing method (version 8). , 2004, The Journal of antimicrobial chemotherapy.

[31]  K. Köhrer,et al.  Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC , 1998, Antimicrobial Agents and Chemotherapy.

[32]  T. Nukiwa,et al.  Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. , 1998, The Journal of antimicrobial chemotherapy.

[33]  T. Wichelhaus,et al.  Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. , 2001, The Journal of antimicrobial chemotherapy.

[34]  Daniel J. Wilson,et al.  Transforming clinical microbiology with bacterial genome sequencing , 2012, Nature Reviews Genetics.

[35]  B. Söderquist,et al.  Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the rpoB gene , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[36]  L. Amaral,et al.  Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus , 2011, BMC microbiology.

[37]  J. Andrews BSAC WORKING PARTY ON SUSCEPTIBILITY TESTING FT. BSAC STANDARDIZED DISC SUSCEPTIBILITY TESTING METHOD , 2001 .

[38]  I. Chopra,et al.  Genetic Basis of Resistance to Fusidic Acid in Staphylococci , 2007, Antimicrobial Agents and Chemotherapy.

[39]  K. Köhrer,et al.  Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. , 1998, The Journal of antimicrobial chemotherapy.

[40]  A. Anderson,et al.  Prospective Screening of Novel Antibacterial Inhibitors of Dihydrofolate Reductase for Mutational Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[41]  A. Tomasz,et al.  Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. , 2013, The Journal of infectious diseases.

[42]  Richard G. Everitt,et al.  Within-Host Evolution of Staphylococcus aureus during Asymptomatic Carriage , 2013, PloS one.

[43]  Martin Goodson,et al.  Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. , 2011, Genome research.

[44]  M. Metzker Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[45]  G. Yılmaz,et al.  Detection and prevalence of inducible clindamycin resistance in staphylococci. , 2007, Journal of medical microbiology.

[46]  L. Peterson,et al.  GyrA sequence analysis of Staphylococcus aureus and methicillin-resistant S. aureus strains selected, in vitro, for high-level ciprofloxacin resistance. , 1993, Diagnostic microbiology and infectious disease.

[47]  Andrew C. Pawlowski,et al.  The Comprehensive Antibiotic Resistance Database , 2013, Antimicrobial Agents and Chemotherapy.

[48]  S. Pyörälä,et al.  Comparison of phenotypic and genotypic detection of penicillin G resistance of Staphylococcus aureus isolated from bovine intramammary infection. , 2005, Veterinary microbiology.

[49]  Daniel J. Wilson,et al.  A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance , 2012, BMJ Open.

[50]  T. Ezaki,et al.  Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant Staphylococcus aureus isolated from ocular infections. , 2006, Diagnostic microbiology and infectious disease.

[51]  Julian Parkhill,et al.  Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study , 2013, The Lancet. Infectious Diseases.

[52]  F. Aarestrup,et al.  Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci. , 2006, The Journal of antimicrobial chemotherapy.

[53]  M. Page,et al.  A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. , 1997, Journal of molecular biology.

[54]  Karen C. Carroll,et al.  Evaluation of the BD Phoenix Automated Microbiology System for Identification and Antimicrobial Susceptibility Testing of Staphylococci and Enterococci , 2006, Journal of Clinical Microbiology.

[55]  K. Köhrer,et al.  Development of Resistance to Ciprofloxacin, Rifampin, and Mupirocin in Methicillin-Susceptible and -ResistantStaphylococcus aureus Isolates , 2000, Antimicrobial Agents and Chemotherapy.

[56]  J. Marimón,et al.  Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples. , 2011, The Journal of antimicrobial chemotherapy.

[57]  M. Sasatsu,et al.  Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. , 2005, International journal of antimicrobial agents.

[58]  D. Persing,et al.  Detection of the Staphylococcal mecA gene by chemiluminescent DNA hybridization , 1995, Journal of clinical microbiology.

[59]  H. Narita,et al.  Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. , 1996, The Journal of antimicrobial chemotherapy.

[60]  A. Myllyniemi,et al.  Comparison of tests for detection of beta-lactamase-producing staphylococci. , 2007, Journal of clinical microbiology.

[61]  R. Howe,et al.  BSAC standardized disc susceptibility testing method (version 11). , 2012, The Journal of antimicrobial chemotherapy.

[62]  J. R. Johnson,et al.  Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data , 2013, The Journal of antimicrobial chemotherapy.

[63]  Ole Lund,et al.  Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. , 2013, The Journal of antimicrobial chemotherapy.

[64]  H. Chen,et al.  Fusidic acid resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in a Taiwanese hospital , 2011, BMC Microbiology.